Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
The last of our three cases reviewing management issues in elderly and frail patients with lung cancer, as covered in a recent webinar discussion I had with experts Paul J. Hesketh from Lahey Clinic and Karen Kelly from Kansas University Medical Center, focuses on treatment of advanced/metastatic NSCLC. Drs. Hesketh and Kelly are two of the world experts in this field that so desperately needs more research and careful thought, given that the median age of patients newly diagnosed with lung cancer in the US is now just over 70, and about a third of patients are frail, but our studies primarily or exclusively include younger, healthy patients. In fact, the figures include the reference of a review article that Dr. Hesketh is just publishing now in the Journal of Thoracic Oncology on treating patients 80 and older with lung cancer (it appears online but hasn't appeared in the actual printed journal yet).
Here is the audio and video versions of the podcast, along with the figures and transcript.
adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-audio-podcast
adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-transcript
adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-figs
As always, we welcome your thoughts and comments.
This program was made possible by an educational grant from OSI Pharmaceuticals, who had no input in its content. We thank them for their support.
Please feel free to offer comments and raise questions in our
discussion forums.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.